PBAC's latest decision on Triptorelin: Recommended with restriction (2021). Considered for Treatment of central precocious puberty (CPP) in children aged 2 years and older with onset before 8 years in girls and 10 years in boys.
PBAC outcome
Recommended with restriction
Restricted
ICER (AUD/QALY)
Cost-min
cost-minimisation analysis
Submissions
2
first 2006
Submissions
2
2006 → 2021
Eligible population
Children with central precocious puberty aged 11 years or younger (girls) or 12 years or younger (boys), with onset before 8 years (girls) or 10 years (boys).
Therapy area
Endocrinology
Line of therapy
First-line
Evidence base
Single-arm
Primary endpoint
Surrogate
Pivotal trial size
44 patients
Key trials
Study 301, Lee 2012, Lee 2014
Comparator
leuprorelin acetate depot 30 mg
Economic model
Cost-minimisation
ICER note
Cost-minimisation analysis; no ICER calculated by design.
Submission history
Nov 2006: Recommended with restriction · Authority Required
Jul 2021: Recommended with restriction · Restricted